All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MDS Hub

MDS Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2023-10-11T08:54:59.000Z

TRANSCEND CLL 004 trial: efficacy and safety of liso-cel in patients with R/R CLL or SLL

By Mark Maitland, Suzanna de Barra, Sabina Ray
Oct 11, 2023
Share:
Learning objective: After reading this article, learners will be able to recall key findings from the TRANSCEND CLL 004 trial and the implications for the treatment of patients with R/R CLL or SLL after BTKi progression and venetoclax failure.

Bookmark this article

The Lymphoma Hub is pleased to present a visual abstract summarizing the latest results from TRANSCEND CLL 004 (NCT03331198).1

Despite advancements in the therapeutic landscape, there remains an unmet need for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), especially after progression from Bruton’s kinase inhibitors (BTKi) or venetoclax failure.1 In the phase I/II TRANSCEND CLL 004 dose-escalation study, lisocabtagene maraleucel (liso-cel) was investigated at two doses in patients with R/R CLL or SLL and a subset of patients who had progressed after BTKi and failed venetoclax treatment.1


Visual Abstract

To download this visual abstract, click below.

Download here

  1. Siddiqi T, Maloney D, Kenderian S, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study. The Lancet. 2023;402:641-654. DOI: 1016/S0140-6736(23)01052-8

More about...
Chronic lymphocytic leukemiaChronic lymphocytic leukemiasLisocabtagene maraleucelTRANSCEND-CLL-004

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

Which treatment do you select for patients with follicular lymphoma after multiple relapses?
0 votes - 6 days left ...

Related articles

Add bookmark

Primary endpoint met in TRANSCEND-CLL-004 trial of liso-cel in R/R CLL

Topline results obtained from the phase II TRANSCEND-CLL-004 trial of liso-cel in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) show that the trial met its primary...

Jan 31, 2023
Add bookmark

Primary endpoint met in TRANSCEND-CLL-004 trial of liso-cel in R/R CLL

Topline results obtained from the phase II TRANSCEND-CLL-004 trial of liso-cel in relapsed/refractory (R/R) chronic lymphocytic...

Jan 31, 2023
Add bookmark

ICML 2019 | TRANSCEND CLL04: are the responses to JCAR017 sustained in patients with R/R CLL/SLL?

ICML 2019 | TRANSCEND CLL04: are the responses to JCAR017 sustained in patients with R/R CLL/SLL?

Jun 26, 2019
Add bookmark

ICML 2019 | TRANSCEND CLL04: are the responses to JCAR017 sustained in patients with R/R CLL/SLL?

ICML 2019 | TRANSCEND CLL04: are the responses to JCAR017 sustained in patients with R/R CLL/SLL?

Jun 26, 2019

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox